| CEO Name | Alexander Hardy |
| Nationality | United Kingdom |
| Net Worth Estimation | $25 million |
Alexander Hardy's estimated net worth of around $25 million stems from his executive compensation as CEO of Genentech, Inc., including salary, bonuses, stock options, and equity awards from both Genentech and parent company Roche Group. His wealth is further reinforced by long-term incentives, performance shares, and accrued benefits tied to Roche's robust financial performance and stock value.
Alexander Hardy's estimated net worth of $25,000,000 places him at 21.4% between the $10,000,000 minimum and $90,000,000 maximum CEO net worth range in the healthcare business category. His net worth is above the category minimum but well below the maximum.
Business Category: Healthcare
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD
Alexander Hardy Performance in Genentech, Inc. (member of the Roche Group)
Alexander Hardy, CEO of Genentech, Inc. (a member of the Roche Group), drives innovative leadership focused on advancing biotechnology and personalized medicine. His decision-making emphasizes strategic investment in research and development, accelerating drug pipelines and fostering collaborations. Under Hardy's leadership, Genentech has strengthened its market position and significantly enhanced performance by bringing groundbreaking therapies to patients worldwide.
Latest News
Genentech, Inc. and Roche Expand Manufacturing and Innovation Facilities in the US
Genentech, a member of the Roche Group, recently broke ground on a $700 million state-of-the-art manufacturing facility in Holly Springs, North Carolina, marking its first East Coast manufacturing site. The facility will create over 1,900 jobs and focus on producing next-generation metabolic medicines, including obesity treatments; Roche CEO Thomas Schinecker emphasized this as part of a $50 billion investment in US manufacturing and R&D. Additionally, Roche launched the Roche Genentech Innovation Center in Boston to foster drug discovery and AI integration, reinforcing their commitment to innovation and expansion.
Source: http://www.roche.com/media/releases/med-cor-2025-08-25